Rheumatology

  • When primary anti-TNF fails in axial spondyloarthritis, consider comorbidities or second anti-TNF

    on January 13th, 2017
    FROM RHEUMATOLOGY Most of the minority of axial spondyloarthritis patients who do not respond to their first tumor necrosis factor inhibitor still meet classification criteria for the condition 5-10 years later, but more than half respond to a second TNFi and most also have comorbidities that could [...]
  • Nailfold analysis can predict cardiopulmonary complications in systemic sclerosis

    on January 12th, 2017
    FROM RHEUMATOLOGY Nailfold videocapillaroscopy can help to predict which patients with systemic sclerosis may develop serious cardiopulmonary complications, according to findings from a Dutch cross-sectional study. While individual autoantibodies seen in systemic sclerosis (SSc) are known to be asso[...]
  • All systemic steroid guidelines for RA offer little guidance

    on January 12th, 2017
    FROM ARTHRITIS CARE & RESEARCH Every current guideline and consensus statement regarding systemic glucocorticoid therapy in rheumatoid arthritis falls short of offering clinicians practical, evidence-based guidance, according to a systematic review of all 15 such documents published in 2011-2015[...]
  • Medicare payments set for infliximab biosimilar Inflectra

    on January 10th, 2017
    Payment for the infliximab biosimilar drug Inflectra will now be covered by Medicare, the drug’s manufacturer, Pfizer, said in an announcement. The Centers for Medicare & Medicaid Services (CMS) included Inflectra (infliximab-dyyb) in its January 2017 Average Sales Price pricing file , which w[...]
  • Giant cell arteritis independently raises risk for venous thromboembolism

    on January 10th, 2017
    FROM ARTHRITIS & RHEUMATOLOGY The risk of venous thromboembolism increases markedly shortly before the diagnosis of giant cell arteritis regardless of glucocorticoid exposure, peaks at the time of diagnosis, and then progressively declines, according to a matched cohort review involving more tha[...]
  • Osteopenia risk up in men with sarcopenia and COPD

    on January 9th, 2017
    FROM CHEST Men experiencing sarcopenia who also have been diagnosed with chronic obstructive pulmonary disease (COPD) are at a significantly higher risk of developing osteopenia and osteoporosis than are men who do not suffer from COPD, according to a new study published in Chest. “Muscle depletio[...]
  • Enthesitis seen in 35% of PsA patients

    on January 9th, 2017
    FROM ARTHRITIS CARE & RESEARCH About one-third of people with psoriatic arthritis have clinical enthesitis, according to results from a prospective cohort study of more than 800 patients. Enthesitis, or soreness and inflammation at sites where soft tissue attaches to bone, is considered to be co[...]
  • Ixekizumab proves highly effective for palmoplantar, scalp psoriasis

    on December 21st, 2016
    EXPERT ANALYSIS FROM THE EADV CONGRESS VIENNA (FRONTLINE MEDICAL NEWS) – Ixekizumab proved markedly more effective than etanercept for treatment of palmoplantar psoriasis in a head-to-head contest in the landmark phase III UNCOVER-3 trial, Alan Menter, MD, reported at the annual congress of the Eu[...]
  • Rheumatology among specialties that continue to see strong Specialty Match Day

    on December 19th, 2016
    Rheumatology saw nearly 97% of its positions filled during the 2016 Specialty Match Day. The specialty had 217 open slots and ended the Dec. 7 match day with only 7 positions unfilled. There were 312 applicants that selected rheumatology as their primary specialty, with 206 applicants being matched.[...]
  • MACRA’s near and potential long-term future outlined for rheumatology

    on December 16th, 2016
    EXPERT ANALYSIS FROM THE ACR ANNUAL MEETING WASHINGTON (FRONTLINE MEDICAL NEWS) – Now that implementation of the Medicare Access and CHIP Reauthorization Act is on rheumatologists’ doorsteps, figuring out what is required in 2017 is imperative to avoid future penalties and maximize the chance of[...]
  • FDA bans powdered gloves

    on December 16th, 2016
    The Food and Drug Administration has banned powdered gloves for use in health care settings, citing “numerous risks to patients and health care workers.” The ban extends to gloves currently in commercial distribution and in the hands of the ultimate user, meaning powdered gloves will have to be [...]
  • OA drug development needs patient-focused approach to biomarkers and outcome measures

    on December 13th, 2016
    Advances in our understanding of the development and treatment of osteoarthritis have led to renewed interest in leveraging these insights to establish more ways to evaluate potential drug candidates in clinical trials, particularly through the use of qualified biomarkers as meaningful outcome measu[...]
  • MRI useful to distinguish between PACNS and neurosarcoidosis

    on December 13th, 2016
    AT THE ACR ANNUAL MEETING WASHINGTON (FRONTLINE MEDICAL NEWS) – MRI can help to differentiate between neurosarcoidosis and primary angiitis of the central nervous system, according to a single-center study comparing the two conditions. Patients with neurosarcoidosis were significantly more likely [...]
Back to top